Sinopharm Group Co Ltd
HKEX:1099
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.1), the stock would be worth HK$45.4 (146% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | HK$18.47 |
0%
|
| 3-Year Average | 0.1 | HK$45.4 |
+146%
|
| 5-Year Average | 0.1 | HK$50.29 |
+172%
|
| Industry Average | 2.1 | HK$888.55 |
+4 711%
|
| Country Average | 1.9 | HK$829.28 |
+4 390%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | 0 | 7.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 5 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 3.2 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 3.2 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 3.2 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 4.8 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 0.6 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 1.2 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 2.1 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 4.7 | 89.6 | |
| DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
5B EUR | 1.4 | -5.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Sinopharm Group Co Ltd
Glance View
Sinopharm Group Co., Ltd., a colossal force in China’s healthcare sector, navigates a complex landscape with the precision and might one might expect of a giant orchestrating a symphony. As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm operates through a broad network, ensuring that life-saving drugs and medical devices seamlessly reach hospitals, clinics, and pharmacies across the nation. Their business thrives by acting as an intermediary, efficiently bridging the gap between countless pharmaceutical manufacturers and healthcare facilities. By managing this extensive logistics and distribution network, Sinopharm not only commands an influential position in the supply chain but also shapes the very infrastructure upon which China's healthcare system depends. With a vast catalog spanning essential medicines, traditional Chinese remedies, and modern medical equipment, Sinopharm generates revenue predominantly through the distribution margins on these products. Beyond its distribution prowess, Sinopharm has strategically expanded upstream and downstream within the healthcare industry. Diversification plays a key role in its business model as the company delves into pharmaceutical manufacturing, health services, and even healthcare logistics. By owning manufacturing facilities, Sinopharm is able to create a closed-loop system for certain medications, capitalizing on the entire value chain from production to retail. Furthermore, the group expands its influence through partnerships and acquisitions, carving out a robust presence in healthcare-related services, research, and development, and retail pharmacies. This multifaceted approach enables Sinopharm to fortify its profitability, reduce dependency on external entities, and enhance its resilience amidst fluctuations in the healthcare landscape. Through its expansive reach and innovative strategy, Sinopharm cements its status as a vital player in both the national and global healthcare arenas.